Host: |
Rabbit |
Applications: |
WB |
Reactivity: |
Human/Rat |
Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Rabbit polyclonal antibody anti-HUWE1 (1-100) is suitable for use in Western Blot research applications. |
Clonality: |
Polyclonal |
Conjugation: |
Unconjugated |
Isotype: |
IgG |
Formulation: |
PBS with 0.05% Proclin300, 50% Glycerol, pH7.3. |
Purification: |
Affinity purification |
Dilution Range: |
WB 1:500-1:1000 |
Storage Instruction: |
Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
Gene Symbol: |
HUWE1 |
Gene ID: |
10075 |
Uniprot ID: |
HUWE1_HUMAN |
Immunogen Region: |
1-100 |
Immunogen: |
A synthetic peptide corresponding to a sequence within amino acids 1-100 of human HUWE1 (NP_113584.3). |
Immunogen Sequence: |
MKVDRTKLKKTPTEAPADCR ALIDKLKVCNDEQLLLELQQ IKTWNIGKCELYHWVDLLDR FDGILADAGQTVENMSWMLV CDRPEREQLKMLLLAVLNFT |
Tissue Specificity | Weakly expressed in heart, brain and placenta but not in other tissues. Expressed in a number of cell lines, predominantly in those from colorectal carcinomas. |
Post Translational Modifications | Phosphorylated on tyrosine.phosphorylation is probably required for its ability to inhibit TP53 transactivation. |
Function | E3 ubiquitin-protein ligase which mediates ubiquitination and subsequent proteasomal degradation of target proteins. Regulates apoptosis by catalyzing the polyubiquitination and degradation of MCL1. Mediates monoubiquitination of DNA polymerase beta (POLB) at 'Lys-41', 'Lys-61' and 'Lys-81', thereby playing a role in base-excision repair. Also ubiquitinates the p53/TP53 tumor suppressor and core histones including H1, H2A, H2B, H3 and H4. Ubiquitinates MFN2 to negatively regulate mitochondrial fusion in response to decreased stearoylation of TFRC. Ubiquitination of MFN2 also takes place following induction of mitophagy.AMBRA1 acts as a cofactor for HUWE1-mediated ubiquitination. Regulates neural differentiation and proliferation by catalyzing the polyubiquitination and degradation of MYCN. May regulate abundance of CDC6 after DNA damage by polyubiquitinating and targeting CDC6 to degradation. Mediates polyubiquitination of isoform 2 of PA2G4. Acts in concert with MYCBP2 to regulate the circadian clock gene expression by promoting the lithium-induced ubiquination and degradation of NR1D1. Binds to an upstream initiator-like sequence in the preprodynorphin gene. Mediates HAPSTR1 degradation, but is also a required cofactor in the pathway by which HAPSTR1 governs stress signaling. |
Protein Name | E3 Ubiquitin-Protein Ligase Huwe1Arf-Binding Protein 1Arf-Bp1Hect - Uba And Wwe Domain-Containing Protein 1Hect-Type E3 Ubiquitin Transferase Huwe1Homologous To E6ap Carboxyl Terminus Homologous Protein 9Hecth9Large Structure Of Ureb1Lasu1Mcl-1 Ubiquitin Ligase E3MuleUpstream Regulatory Element-Binding Protein 1Ure-B1Ure-Binding Protein 1 |
Database Links | Reactome: R-HSA-6798695Reactome: R-HSA-983168 |
Cellular Localisation | CytoplasmNucleusMitochondrionMainly Expressed In The Cytoplasm Of Most TissuesExcept In The Nucleus Of SpermatogoniaPrimary Spermatocytes And Neuronal CellsRecruited To Mitochondria Following Interaction With Ambra1 |
Alternative Antibody Names | Anti-E3 Ubiquitin-Protein Ligase Huwe1 antibodyAnti-Arf-Binding Protein 1 antibodyAnti-Arf-Bp1 antibodyAnti-Hect - Uba And Wwe Domain-Containing Protein 1 antibodyAnti-Hect-Type E3 Ubiquitin Transferase Huwe1 antibodyAnti-Homologous To E6ap Carboxyl Terminus Homologous Protein 9 antibodyAnti-Hecth9 antibodyAnti-Large Structure Of Ureb1 antibodyAnti-Lasu1 antibodyAnti-Mcl-1 Ubiquitin Ligase E3 antibodyAnti-Mule antibodyAnti-Upstream Regulatory Element-Binding Protein 1 antibodyAnti-Ure-B1 antibodyAnti-Ure-Binding Protein 1 antibodyAnti-HUWE1 antibodyAnti-KIAA0312 antibodyAnti-KIAA1578 antibodyAnti-UREB1 antibodyAnti-HSPC272 antibody |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance